Jounce Therapeutics

$3.44
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.08 (-2.27%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell JNCE and other stocks, options, ETFs, and crypto commission-free!

About JNCE

Jounce Therapeutics, Inc. Common Stock, also called Jounce Therapeutics, is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Read More Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Employees
115
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
116.10M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
104.79K
High Today
$3.59
Low Today
$3.43
Open Price
$3.57
Volume
138.65K
52 Week High
$7.35
52 Week Low
$2.66

Collections

JNCE Earnings

-$0.49
-$0.35
-$0.20
-$0.06
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 12, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.